VBI-1901 is a vaccine against cytomegalovirus or CMV. It is designed to kill glioblastoma and medulloblastoma tumor cells infected with CMV, as many are.
The immune system already targets cells infected by viruses. VBI-1901’s goal is to boost the immune response to them.
CMV inside tumor cells generate proteins called viral antigens that travel to the cells’ surface.
VBI-1901 is designed to coax the body to produce antibodies and white blood cells that can kill tumor cells with these antigens.
VBI-1901 also includes a protein called granulocyte-macrophage colony-stimulating factor that gives the vaccine more punch. It boosts its ability to trigger an immune response by attracting immune dendritic cells to the site where the vaccine is injected
VBI-1901 is an immunotherapy cancer vaccine that will stimulate the patient’s own immune system to identify and kill GBM cancer cells.
VBI-1901 is co-administered with GM-CSF via the intradermal route.
Clinical Trial NCT03382977: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- This is a two-part, dose-escalation study to define the safety, tolerability, and optimal dose level of candidate GBM vaccine VBI-1901 with subsequent extension of optimal dose level in recurrent GBM subjects.
- Part A: Dose-escalation phase to define the safety, tolerability, and optimal dose level of VBI-1901 in recurrent GBM patients. This phase is expected to enroll up to 18 patients in three dose cohorts.
- Part B: A subsequent extension of the optimal dose level, as defined in the dose-escalation phase. This phase is expected to enroll an expanded cohort of approximately 10 additional patients.